LipimetiX
Natick · Founded 2012
About LipimetiX
LipimetiX Development was established as a joint venture between Capstone Therapeutics Corp. (OTCQB: CAPS), and LipimetiX, Inc. We are a privately held biopharmaceutical company created to develop a novel class of drugs to treat refractory hypercholesterolemia and hypertriglyceridemia, acute pancreatitis, coronary artery, and peripheral artery diseases by rapidly decreasing arterial cholesterol content and inflammation. LipimetiX's technology is based upon a platform of chimeric peptide mimetics of apolipoprotein E, a critical protein that directs cholesterol and triglyceride rich lipoproteins to receptors on the liver. LipimetiX's base peptide, AEM-28, has demonstrated remarkable VLDL cholesterol and triglyceride reductions in Phase 1 and Phase 2 human clinical trials. More potent analogs of AEM-28 are currently being developed for acute pancreatitis, refractory hypertriglyceridemia and genetically induced refractory hypercholesterolemia, orphan indications that lead to early cardiovascular disease. AEM-28 has been granted orphan drug designation from the FDA.
Company Facts
- Founded: 2012
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $1.0M
- Last round: Series Unknown (Sep 2016)
- Website: http://www.lipimetix.com/
- Phone: +1 (508)651-3715
Social Profiles
Canonical: https://fsome.com/organization/lipimetix-8268040 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.